TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16393306
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg administered i.v. over 20 min
Study: 15233978
Drug: Amlodipine/benazepril combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/benazepril combination therapy (5 mg and 10 mg with 40 mg benazepril)
Study: 15233978
Drug: Benazepril hydrochloride
Normalized name: Benazepril Hydrochloride
DrugBank: Benazepril (DB00542)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benazepril hydrochloride (40 mg) alone
Study: 11316720
Drug: Oral famciclovir
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral famciclovir 500 mg three times daily
Study: 11316720
Drug: Oral aciclovir
Normalized name: acyclovir Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aciclovir 800 mg five times daily
Study: 3555587
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg + hydrochlorothiazide (HCTZ) 25 mg once daily
Study: 18058818
Drug: Meloxicam 7.5
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 7.5 mg/day for 10-14 days before surgery
Study: 15319157
Drug: diclofenac‐Na 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac‐Na 0.1% Emulgel gel
Study: 15319157
Drug: vehicle Emulgel
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle Emulgel gel
Study: 11149011
Drug: Weekly i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly i.v. bolus injection of 5‐fluorouracil 400 mg/m2 plus leucovorin 20 mg/m2
Study: 11149011
Drug: Monthly i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly i.v. bolus injection of 5‐fluorouracil 425 mg/m2 plus leucovorin 20 mg/m2 for 5 consecutive days every 4 or 5 weeks
Study: 11149011
Drug: Monthly arm
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly arm
Study: 9076817
Drug: Miconazole gel
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole gel (25 mg, four times daily)
Study: 3948857
Drug: WIEXP (water
Approvals — FDA: no, EMA: no, PMDA: no
Description: WIEXP (water immersion with blood volume expansion by intravenous infusion of 2.0 L of isotonic saline for 2 hours)
Study: 3948857
Drug: WIHEM (water
Approvals — FDA: no, EMA: no, PMDA: no
Description: WIHEM (water immersion with blood volume reduction by loss of 0.5 L of blood during 30 minutes)
Study: 25265927
Drug: DECT mode,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DECT mode, 0.5 ml per kg of patient weight CM at injection rate=(weight × 0.5 ml/kg)/(4+scan time)
Study: 25265927
Drug: Single‐energy CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single‐energy CT 70 ml CM at injection rate of 5 ml/s
Study: 21900307
Drug: Questionnaire using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Questionnaire using the term 'nonspecific methods of treatment'
Study: 17288679
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg plus hydrochlorothiazide 12.5 mg
Study: 17288679
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg plus hydrochlorothiazide 12.5 mg
Study: 16053996
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (low-dose angiotensin receptor blocker) for 2 years
Study: 8674397
Drug: Cisapride (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (20 mg four times a day)
Study: 3881327
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid 375 mg daily
Study: 29744900
Drug: Fluconazole (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (loading dose 25 mg kg‐1; maintenance dose 12 mg kg‐1 day‐1 for infants <30 weeks or 20 mg kg‐1 day‐1 for infants ≥30 weeks' corrected gestational age)
Study: 29744900
Drug: Micafungin (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin (loading dose 15 mg kg‐1 day‐1; maintenance dose 10 mg kg‐1 day‐1)
Study: 23130467
Drug: Split drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Split drug regimen (two times a day)
Study: 23130467
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily regimen
Study: 16278523
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (verapamil/trandolapril or atenolol/hydrochlorothiazide)
Study: 16278523
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (verapamil/trandolapril/hydrochlorothiazide or atenolol/hydrochlorothiazide/trandolapril)
Study: 16278523
Drug: Monotherapy (verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (verapamil or atenolol)
Study: 8560999
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg estradiol valerate
Study: 8560999
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg norethisterone acetate
Study: 18581513
Drug: Dichloroacetate (DCA)
Normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloroacetate (DCA) 40 mg/kg intravenously
Study: 8806289
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further local treatment
Study: 6427416
Drug: FAM combination
Normalized name: fam-trastuzumab deruxtecan-nxki Injection [Enhertu]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAM combination (5‐fluorouracil, doxorubicin, and mitomycin C) - simultaneous administration
Study: 6427416
Drug: FAM combination
Normalized name: fam-trastuzumab deruxtecan-nxki Injection [Enhertu]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAM combination (5‐fluorouracil, doxorubicin, and mitomycin C) - sequential administration
Study: 30827300
Drug: Oral massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral massage method with non-nutritive sucking, stimulating swallowing function, and SandraFucile, once a day for 14 consecutive days.
Study: 30827300
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment of preterm infants without oral intervention.
Study: 24365208
Drug: Intramuscular ergometrine
Normalized name: Ergometrine
DrugBank: Ergometrine (DB01253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ergometrine (0.5mg)
Study: 18639450
Drug: Irinotecan (IRI),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (IRI), Leucovorin (LV), and bolus 5-fluorouracil (5FU) administered weekly (80 mg/m2 IV IRI, 200 mg/m2 LV, 450 mg/m2 bolus 5FU) for six cycles followed by pelvic irradiation plus 5FU.
Study: 18639450
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: Leucovorin (LV) and bolus 5-fluorouracil (5FU) (200 mg/m2 LV and 450 mg/m2 IV bolus 5FU) for six cycles followed by pelvic irradiation plus 5FU.
Study: 15947501
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acetyl‐L‐carnitine, n‐3 fatty acids, and coenzyme Q10 (Phototrop)
Study: 12757966
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg sublingual buprenorphine tablets administered four times a day
Study: 1707646
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enalapril and sulindac
Study: 30420616
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months (3M) adjuvant chemotherapy
Study: 30420616
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months (6M) adjuvant chemotherapy
Study: 27465309
Drug: Contamination-focused exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contamination-focused exposure therapy (3 sessions of 30 minutes each)
Study: 27465309
Drug: Contamination-focused exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contamination-focused exposure therapy
Study: 24273218
Drug: Whole soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole soy (40 g soy flour)
Study: 24273218
Drug: Purified daidzein
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified daidzein (63 mg)
Study: 20635286
Drug: REMAS intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: REMAS intervention in psychosocial outpatient treatment
Study: 16521631
Drug: Parnaparin 6400
Normalized name: parnaparin
DrugBank: Parnaparin (DB09260)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parnaparin 6400 IU subcutaneously once daily for 7 days
Study: 16521631
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (IV bolus of 5000 IU followed by infusion of 800 to 1000 IU/hour for 48 hours, then 5000 IU subcutaneously every 6 hours for 5 days)
Study: 8681660
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (800 micrograms beclomethasone dipropionate)
Study: 1992412
Drug: Amoxicillin, 500
Normalized name: Amoxicillin, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin, 500 mg three times daily for 14 days
Study: 19100012
Drug: Tongxinluo therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongxinluo therapy
Study: 9356558
Drug: Personal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal therapy
Study: 3542088
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of dry cold air (causing significant bronchoconstriction)
Study: 3542088
Drug: Methacholine test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine test without prior cold air inhalation
Study: 29848147
Drug: Seltorexant 40
Normalized name: Seltorexant
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seltorexant 40 mg for five days
Study: 20308694
Drug: Comprehensive multinutrient
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive multinutrient supplement (SUPP)
Study: 15739035
Drug: Alendronate (Aln,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (Aln, 10 mg/day) plus Raloxifene (Rlx, 60 mg/day)
Study: 15739035
Drug: Alendronate (Aln,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (Aln, 10 mg/day) plus Hormone Replacement Therapy (HRT, 0.625 mg/day conjugated equine estrogens plus 2.5 mg/day medroxyprogesterone acetate)
Study: 15739035
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) alone
Study: 11994888
Drug: Risperidone 0.5-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 0.5-2 mg/day
Study: 11994888
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of rivastigmine and risperidone
Study: 10349921
Drug: Vecuronium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium administered with sevoflurane 2% (group 2)
Study: 10349921
Drug: Vecuronium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium administered with sevoflurane 2% after 30 min (group 3)
Study: 10349921
Drug: Vecuronium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium administered with sevoflurane 2% after 60 min (group 4)
Study: 8602306
Drug: Depot goserelin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot goserelin, 3.6 mg subcutaneous implant given monthly
Study: 8602306
Drug: Danazol, 200
Normalized name: Danazol, 200 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol, 200 mg two times per day
Study: 1760910
Drug: Senna tablets
DrugBank: Senna leaf (DB15889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senna tablets
Study: 1760910
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no bowel preparation)
Study: 1760910
Drug: Senna tablets
DrugBank: Senna leaf (DB15889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senna tablets and Sodium picosulphate powder
Study: 1760910
Drug: Laxatives (general)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxatives (general)
Study: 6109500
Drug: Almitrine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine (1.5 mg/kg over a period of one hour)
Study: 31087640
Drug: Chemotherapy and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and/or tumour bed boost radiotherapy (TBBR)
Study: 28748002
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum folate concentrations (>45.3 nmol/L)
Study: 24228854
Drug: Monday to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monday to Saturday rehabilitation (additional Saturday rehabilitation comprising physiotherapy and occupational therapy)
Study: 10792560
Drug: HRT (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (2 mg oestradiol valerate for the first 3 months with the addition of 10 mg medroxyprogesterone for 10 days every third month thereafter)
Study: 30095022
Drug: Vitamin D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin D2 supplement 40,000 IU/week
Study: 22410658
Drug: Topical 0.25%
Normalized name: permethrin topical 0.25% topical kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.25% timolol maleate gel
Study: 19156926
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (TMZ) treatment
Study: 17227902
Drug: Topotecan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.5 mg/m2 for 5 days every 21 days
Study: 15753495
Drug: Landiolol (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (0.3 mg.kg(‐1))
Study: 15753495
Drug: Landiolol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (0.1 mg.kg(‐1))
Study: 15753495
Drug: Landiolol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (0.1 and 0.3 mg.kg(‐1))
Study: 11948832
Drug: NC100150 (between
Approvals — FDA: no, EMA: no, PMDA: no
Description: NC100150 (between 0.75 and 6 mg of Fe/kg of body weight)
Study: 11948832
Drug: High-dose NC100150
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose NC100150
Study: 9465799
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone (400 micrograms intravenously every 8 hours four times)
Study: 2165899
Drug: Fluocortolone (15-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocortolone (15-30 mg)
Study: 366721
Drug: Benoxaprofen (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benoxaprofen (300 mg on the first day followed by 100 mg twice daily)
Study: 16366740
Drug: Herbal supplement
Normalized name: LYDIA PINKHAM Herbal Supplement Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal supplement containing 600 mg black tea extract (60% polyphenols, 20% caffeine) and 442 mg guarana extract (36% caffeine)
Study: 11297904
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg CQ
Study: 11297904
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg CQ
Study: 3283227
Drug: Betaxolol, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol, 20 mg/day
Study: 3283227
Drug: Verapamil, 240‐480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil, 240‐480 mg/day
Study: 27719677
Drug: Community health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community health workers' knowledge and practice regarding pre-eclampsia identification and treatment
Study: 23277147
Drug: Intragastric nitrate
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragastric nitrate administration in BPSDL rats
Study: 17522618
Drug: L-5-methyltetrahydrofolate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-methyltetrahydrofolate (1 mg)
Study: 11123867
Drug: Primary systemic
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary systemic chemotherapy
Study: 8833458
Drug: 0.02% cinnamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02% cinnamic aldehyde in ethanol (patch test)
Study: 8833458
Drug: Patch test
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch test sensitivity
Study: 6740101
Drug: Oral trivalent
Normalized name: poliomyelitis oral, trivalent, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trivalent poliovirus vaccine (OPV)
Study: 6740101
Drug: Injectable trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable trivalent poliovirus vaccine (IPV)
Study: 19844113
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 0.066 mg/kg/day
Study: 10695417
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg TID for 2 weeks)
Study: 8942586
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) at a dose of 15 micrograms/kg
Study: 8942586
Drug: Placebo lozenge/IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenge/IV fentanyl
Study: 6377878
Drug: Intravenous cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cimetidine plus a blinded nasogastric tube
Study: 6377878
Drug: Intravenous cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cimetidine plus nasogastric suction
Study: 30185428
Drug: Multisystemic Therapy‐Health
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisystemic Therapy‐Health Care (6-month home‐ and community‐based treatment)
Study: 30185428
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control group (weekly family supportive counseling for 6 months)
Study: 23117724
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment (aspirin 100mg plus clopidogrel 75 mg/d)
Study: 18370571
Drug: Omega-3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFAs (3.4 g/d)
Study: 15728439
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (120 mg, one capsule/day for 6 weeks)
Study: 15728439
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching capsule for 6 weeks)
Study: 12971422
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols (2.3 g per day)
Study: 10550273
Drug: roxithromycin 150
Normalized name: roxithromycin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin 150 mg twice daily for a mean of 26 days (range 17-35 days)
Study: 1794921
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of new medication
Study: 1794921
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of new medication
Study: 6135635
Drug: Somatostatin infusion
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin infusion at a constant rate of 250 μg/h from 22.00 h until 07.00 h
Study: 6135635
Drug: Control test
Normalized name: CHEK-STIX URINALYSIS CONTROL TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control test (saline infusion)
Study: 31580005
Drug: Lowest dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest dose resulting in 24-hour lasting purpura
Study: 31580005
Drug: Lowest dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest dose resulting in vessel disappearance observed by dermoscope
Study: 25249415
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g cinnamon twice a day for 12 weeks
Study: 22251435
Drug: Infliximab induction
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab induction therapy (5 or 10 mg/kg every 8 weeks beginning at week 14)
Study: 22251435
Drug: Infliximab treatment
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab treatment with CRP normalization (decrease from 0.5 mg/dL at baseline to < 0.5 mg/dL at week 14)
Study: 22251435
Drug: Infliximab treatment
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab treatment at week 14 with low CRP levels
Study: 15652906
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone analogue (1 month before procedure)
Study: 15652906
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone analogue
Study: 14563391
Drug: Tin(II) chloride
Normalized name: Tin(II) fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tin(II) chloride at concentrations of <0.5, 161, 264, and 529 mg/kg in 250 ml tomato juice
Study: 14563391
Drug: Tin migrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tin migrated from packaging at concentrations of <0.5, 201, and 267 mg/kg in 250 ml tomato soup
Study: 10397651
Drug: HA-coated TPS
Normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HA-coated TPS implants